Melanoma therapy produces positive mid-stage data

Researchers for GlaxoSmithKline and Synta Pharmaceuticals say a mid-stage study of elesclomol produced "statistically significant" data on progression-free survival of patients with metastatic melanoma.

"These data, combined with earlier clinical and pre-clinical data we have presented for elesclomol, support our belief that oxidative stress induction is a promising new approach to cancer therapy in melanoma and, potentially, other cancer types," said Eric Jacobson, M.D., Synta's CMO.

- here's the press release
- read the AFX report

Related Articles:
Synta outlines cash flow from Glaxo pact
Synta scores $1.1B deal with GSK
Synta therapy slows spread of melanoma
Synta gets fast track for cancer therapy